



COPY PAPERS  
ORIGINALLY FILED

RECEIVED  
JUL 03 2002  
Sheet 4 of 10

OTHER DOCUMENTS Continued

Modulators of Multi Drug  
TECH CENTER 100012900

RO	28	Tasaka, S et al, "Synthesis of 2-Phenylimidazo [2,1-b]benzothiazole Derivatives as Modulators of Multi-Drug Resistance for Tumor Cells". J. Heterocyclic Chem., 34, pg. 1763-1767 (1997)
RO	29	Monihira, K. et al, "Synthesis and Evaluation of Artificial Taxoids with Antitumor and Multi-Drug resistance Reversing Activities". Bioorganic & Medicinal Chemistry Letters, 8, pg. 2977-2982 (1998)
RO	30	Monihira, K. et al, "Synthesis of C-Ring Aromatic Taxoids and Evaluation of Their Multi-Drug Resistance reversing activity". Bioorganic & Medicinal Chemistry Letters 8, pg. 2973-2976, (1998)
RO	31	Kobayashi, J. et al, "Modulation of the Multidrug Resistance by a Taxuspinine C and Other Taxoids from Japanese Yew". Bioorganic & Medicinal Chemistry Letters 8, pg. 1555-1558, (1998)
RO	32	Kobayashi, J. et al, "Effects of Taxoids from <i>taxus cuspidata</i> on microtubule depolymerization and vincristine accumulation in MDR cells". Bioorganic & Medicinal Chemistry Letters 7, pg. 393-398 (1997)
RO	33	Hosoyama, H. et al, "Modulation of Multidrug Resistance in Tumor Cells by Taxinine derivatives". Bioorganic & Medicinal Chemistry Letters, 9, pg 389-394, (1999)
RO	34	Kam, T. et al, "Reversal of Multidrug resistance (MDR) by aspidofractinine-type indole alkaloids". Bioorganic & Medicinal Chemistry Letters, 8, pg. 2769-2772, (1998)
RO	35	Tanabe, H. et al, "Newly Synthesized Dihydropyridine Derivatives as Modulators of P-Glycoprotein-mediated Multidrug Resistance". Bioorganic & Medicinal Chemistry Letters, 6, pg. 2219-2227 (1998)
RO	36	Sawanishi, H. et al, "Structure-activity Relationships of Diamines, Dicarboxamides, and Disulfonamides on Vinblastine accumulation in P388/ADR Cells". Chem. Pharm. Bull. 7, pg. 1459-1462, (1994)
RO	37	Hooijberg, J. et al, "Modulation by (iso)flavonoids of the ATPase activity of the multidrug resistance protein". FEBS Letters, 413, pg. 344-348, (1997)
RO	38	Sarkadi, B. et al, "Interaction of bioactive hydrophobic peptides with the human multidrug transporter". The FASEB Journal, 8, pg. 766-770, (1994)
RO	39	Pereira, E. et al, "Reversal of Multidrug Resistance by Verapamil analogues". Biochemical Pharmacology, vol. 50, no. 4, pg. 451-457, (1995)
RO	40	Pommerenke, E. et al, "Activity of various amphiphilic agents in reversing multidrug resistance of L1210 cells". Cancer Letters, 55, pg. 17-23, (1990)
RO	41	Kiue, A. et al, "Activities of Newly Synthesized Dihydropyridines in Overcoming of Vincristine Resistance, Calcium Antagonism, and Inhibition of Photoaffinity labeling of P-Glycoprotein In Rodents" Cancer Research, 50, pg. 310-317, (1990)
RO	42	Ford, J. et al, "Structural Features Determining Activity of Phenothiazines and Related Drugs for Inhibition of Cell Growth and Reversal of Multidrug resistance". Molecular Pharmacology, 35, pg. 105-115
RO	43	Nogae, I. et al, "Analysis of structural features of dihydropyridine analogs needed to reverse multidrug resistance and to inhibit photoaffinity labeling of P-glycoprotein". Biochemical Pharmacology, 38, pg. 519-527, (1989)
RO	44	Pearce, H. et al, "Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multidrug resistance". Proc. Natl. Acad. Sci., 86, pg. 5128-5132 (1989)
RO	45	Kirk, J. et al, "Reversal of P-glycoprotein-mediated multidrug resistance by pure anti-oestrogens and novel tamoxifen derivatives." Biochemical Pharmacology, 48, pg. 277-285, (1994)
RO	46	Gekeler, V. et al, "The specific bisindolymaleimide PKC-inhibitor GF 109203x efficiently modulates MRP-Associated Multiple drug resistance". Biochemical and Biophysical research communications, 206, pg. 119-126, (1995)
RO	47	Ford, J. et al, "Cellular and Biochemical Characterization of Thioxanthenes for Reversal of Multidrug resistance in Human and Murine Cell Lines". Cancer Research, 50, pg. 1748-1756, (1990)
RO	48	Kadam, S. et al, "Reversal of Multidrug Resistance by Two Novel Indole Derivatives". Cancer Research, 52, pg. 4735-4740, (1992)
RO	49	Dellinger, M. et al, "Structural Requirements of Simple Organic Cations for Recognition by Multidrug-resistant cells". Cancer research, 52, pg. 6385-6389, (1992)
RO	50	Horton, J. et al, "Pharmacological Characterization of N-Substituted Phenoxazines Directed toward reversing vinca alkaloid resistance in multidrug-resistant cancer cells". Molecular Pharmacology, 44, pg. 552-559, (1993)
RO	51	Smith, C. et al, "Welwitindolinone Analogues that reverse P-Glycoprotein-Mediated Multiple drug Resistance". Molecular Pharmacology, 47, pg. 241-247, (1995)
RO	52	Zhang, L. et al, "Characterization of Prenylcysteines that interact with P-glycoprotein and inhibit drug transport in tumor cells". The Journal of Biological Chemistry, 270, pg. 22859-22865 (1995)
RO	53	Hofmann, J. et al, "Mechanism of action of dextrinulidipine-HC1 (B8509-035), a new potent modulator of multidrug resistance". Biochemical Pharmacology, 49, pg. 603-609 (1995)
RO	54	Wakusawa, S. et al, "Overcoming of Vinblastine Resistance by Isoquinolinesulfonamide compounds in Adriamycin-Resistant Leukemia Cells". Molecular Pharmacology, 41, 1034-1038 (1992)
RO	55	Eliason, J. et al, "Novel Dithiane analogues of tiapamil with high activity to overcome multidrug resistance in vitro". Biochemical Pharmacology, 50, pg. 187-196, (1995)
RO	56	Bhat, U. et al, "A structure-Function Relationship among Reserpine and Yohimbine Analogues in Their Ability to Increase expression of <i>mdr1</i> and P-Glycoprotein in a human colon carcinoma cell line". Molecular Pharmacology, 48, pg. 682-689 (1995)



COPY PAPERS  
ORIGINAL FILED

RECEIVED  
P&G Cas 8375  
Sheet 5 of 10

OTHER DOCUMENTS Continued

JUL 03 2002

RO	57	Borrel, M. et al, "The effect of crown ethers, tetraalkylammonium salts, and polyoxyethylene amphiphiles on pirarubicin incorporation in K562 resistant cells" <i>Biochemical Pharmacology</i> , 50, pg. 1245-1255, (1995)
RO	58	T. foli, G. et al, "Structure-Activity Relationship of verapamil analogs and reversal of multidrug resistance" <i>Biochemical Pharmacology</i> , 50, pg. 1245-1255, (1995)
RO	59	Christensen, J. et al, "Reversal of multidrug resistance <i>in vivo</i> by dietary administration of the phytochemical Indole-3-Carbinol", <i>Cancer Research</i> , 56, pg. 574-581, (1996)
RO	60	Barnes, K. et al, "Steroid Transport, accumulation, and antagonism of P-Glycoprotein in Multidrug resistant cells" <i>Biochemistry</i> , 35, pg. 4820-4827, (1996)
RO	61	Frappier, F. et al, "Bisbenzylisoquinolines as Modulators of Chloroquine Resistance in Plasmodium falciparum and multidrug resistance in Tumor cells" <i>Antimicrobial Agents and Chemotherapy</i> , June, pg. 1476-1481, (1996)
RO	62	Nakamura, S. et al, "Inhibition of P-Glycoprotein-Dependent Multidrug Resistance by an Isoquinolinesulfonamide Compound H-87 in Rat Ascites Hepatoma AH66 Cells" <i>Biol. Pharm. Bull.</i> , 19, pg. 886-889, (1996)
RO	63	Hidaka, H. et al, "Isoquinolinesulfonamides, Novel and Potent Inhibitors of Cyclic Nucleotide dependent Protein Kinase and Protein Kinase C", <i>Biochemistry</i> , 23, pg. 5036-5041, (1984)
RO	64	Chou, T. et al, "Reversal of anticancer multidrug resistance by the ardeemins" <i>Proc. Natl. Acad. Sci.</i> , 95, pg. 8369-8374, (1998)
RO	65	Vanhoefer, U. et al, "PAK-104P, a Pyridine analogue, Reverses Paclitaxel and Doxorubicin Resistance in cell Lines and Nude Mice Bearing Xenografts that overexpress the multidrug resistance protein" <i>Clinical Cancer Research</i> , 2, pg. 369-377 (1996)
RO	66	Chandhary, P. et al, "Induction of Multidrug Resistance in Human Cells by Transient Exposure to different Chemotherapeutic Drugs" <i>Journal of the National Cancer Institute</i> , 85, pg. 632-639 (1993)
RO	67	Sharom, F. et al, "Linear and cyclic peptides as substrates and modulators of P-glycoprotein: peptide binding and effects on drug transport and accumulation" <i>Biochem. Journal</i> , 333, pg. 621-630 (1998)
RO	68	Desrayaud, S. et al, "Effect of the Mdr1a P-Glycoprotein Gene disruption on the tissue distribution of SDZ PSC 833, a multidrug Resistance-Reversing Agent, in Mice." <i>The Journal of Pharmacology and Experimental Therapeutics</i> , 285, pg. 438-443 (1998)
RO	69	Watanabe, T. et al, "Effect of SDZ PSC 833 ([3'-keto-Bmt]-[Val]-cyclosporin) on serum protein binding and distribution to blood cells of doxorubicin, vincristine and etoposide <i>in vitro</i> " <i>Anti-Cancer Drugs</i> , 8, pg. 400-404 (1997)
RO	70	Germann, U. et al, "Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance <i>in vitro</i> " <i>Anti-cancer drugs</i> , 8, pg. 125-140 (1997)
RO	71	Shah, A. et al, "6,12-Dihydro-1-benzopyrano [3,4-b][1,4] benzothiazin-6-ones: Synthesis and mdr Reversal in Tumor Cells" <i>Anticancer Research</i> , 18, pg. 3001-3004 (1998)
RO	72	Pajeva, I. et al, "Molecular Modeling of Phenothiazines and Related Drugs as multidrug resistance modifiers: A Comparative molecular field analysis study" <i>Journal of Medicinal Chemistry</i> , 41, pg. 1815-1826 (1998)
RO	73	Pajeva, I. et al, "QSAR and Molecular Modelling of Catamphiphilic Drugs Able to Modulate Multidrug resistance in Tumors" <i>Quant. Struct. - Act. Relat.</i> , 16, pg. 1-10 (1997)
RO	74	Atadja, P. et al, "PSC-833, a frontier in modulation of P-glycoprotein mediated multidrug resistance", <i>Cancer and Metastasis Reviews</i> , 17, pg. 163-168, (1998)
RO	75	Fields, A. et al, "PSC833: initial clinical results in refractory ovarian cancer patients" <i>Current Opinion in Oncology</i> , 10, pg. S21 (1998)
RO	76	Demeule, M. et al, "Molecular Interactions of Cyclosporin A with P-glycoprotein" <i>The Journal of Biological Chemistry</i> , 272, pg. 6647-6652 (1997)
RO	77	Pourtier-Manzanedo, A. et al, "SDZ PSC 833 and SDZ 280-446 are the most active of various resistance-modifying agents in restoring rhodamine-123 retention within multidrug resistant P388 cells" <i>Anti-Cancer Drugs</i> , 3, pg. 419-425 (1992)
RO	78	Jachaz, B. et al, "SDZ 280-125: a cyclopeptide endowed with an <i>In vitro</i> cyclosporin A-like profile of activity for the reversion to the P-glycoprotein-mediated multidrug resistance of tumor cells", <i>Anti-Cancer Drugs</i> , 5, pg. 313-320 (1994)
RO	79	Twentyman, Peter R., "Cyclosporins as drug resistance modifiers", <i>Biochemical Pharmacology</i> , 43, pg. 109-117, (1992)
RO	80	Germann, U. et al, "Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP" <i>Anti-Cancer Drugs</i> , 8, pg. 141-155 (1997)
RO	81	Dantzig, A. et al "Reversal of P-Glycoprotein-mediated Multidrug Resistance by a Potent Cyclopropyldibenzosuberance Modulator, LY335979" <i>Cancer Research</i> , 56, pg. 4171-4179, (1996)
RO	82	Starling, J. et al, "Pharmacological Characterization of LY335979: A Potent Cyclopropyldibenzosuberance Modulator of P-Glycoprotein" <i>Advan. Enzym. Regul.</i> , 37, pg. 335-347, (1997)
RO	83	Pfister, J. et al, "Methanodibenzosuberipiperazines as Potent Multidrug Resistance Reversal Agents" <i>Organic &amp; Medicinal Chemistry Letters</i> , 5, pg. 2473-2476 (1995)

50, pg. 2069-2076 (1995)



COPY OF PAPERS  
ORIGINALLY FILED

RECEIVED

P&G Case 8375  
FORM PTO-1449  
Sheet 6 of 10

OTHER DOCUMENTS Continued 03 2002

RO	84	Klopman, G. et al. "Structure-Activity study and Design of Multidrug-resistant Reversal Compounds by a Computer Automated Structure Evaluation Methodology" <i>Chemical Research</i> , 1052099, 4121-4129 (1992)
RO	85	Klopman, G. et al. "Quantitative Structure-Activity Relationship of Multidrug-Resistance Reversal Agents" <i>Molecular Pharmacology</i> , 52, pg. 323-334 (1997)
RO	86	Legrand, O. et al. "NEOPLASIA: Simultaneous Activity of MRP1 and Pgp Is Correlated with in vitro resistance to Daunorubicin and with In vivo resistance in Adult Acute Myeloid Leukemia" <i>Blood</i> , 94, pg. 1046-1056 (1999)
RO	87	Leith, C. et al. "NEOPLASIA: Frequency and Clinical Significance of the Expression of the Multidrug resistance proteins MDR1/P-Glycoprotein, MRP1, and LRP in Acute Myeloid Leukemia. A Southwest Oncology Group Study." <i>Blood</i> , 94, pg. 1086-1099 (1999)
RO	88	Mealey, K. et al. "Immunosuppressant inhibition of P-glycoprotein function is independent of drug-induced suppression of Peptide-prolyl isomerase and calcineurin activity" <i>Cancer Chemother Pharmacol</i> , 44, pg. 152-158, (1999)
RO	89	Dey, S. et al. "A single amino acid residue contributes to distinct mechanisms of inhibition of the human multidrug transporter by stereoisomers of the dopamine receptor antagonist flupentixol." <i>Biochemistry</i> , 38, pg. 6630-6639 (1999)
RO	90	Woo, T. et al. "The transmembrane domains of the human multidrug resistance P-glycoprotein are sufficient to mediate drug binding and trafficking to the cell surface." <i>The Journal of Biological Chemistry</i> , 274, pg. 24759-24765, (1999)
RO	91	Tunggal, J. et al. "Influence of cell concentration in limiting the therapeutic benefit of P-glycoprotein reversal agents" <i>Int. J. Cancer</i> , 81, pg. 741-747 (1999)
RO	92	Zheleznova, E. et al. "A structure-based mechanism for drug binding by multidrug transporters, pg. 39-43. (year)"
RO	93	Di Pierro, A. et al. "P-glycoprotein-mediated resistance to chemotherapy in cancer cells: using recombinant cytosolic domains to establish structure-function relationships" <i>Brazilian J. Med. Biol. Research</i> , 32, pg. 925-939 (1999)
RO	94	Grey, M. et al. "Effect on cell kill of addition of multidrug resistance modifiers cyclosporin A and PSC 833 to cytotoxic agents in chronic lymphocytic leukaemia" <i>Leukemia Research</i> , 23, pg. 29-35 (1999)
RO	95	Dey, S. et al. "Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein" <i>Proc. Natl. Acad. Sci.</i> , 94, pg. 10594-10599 (1997)
RO	96	Seeling, A. "A general pattern for substrate recognition by P-Glycoprotein" <i>Eur. Journal Biochem.</i> , 251, pg. 252-261 (1998)
RO	97	Tmej, C. et al. "A Combined Hansch/Free-Wilson Approach as Predictive Tool in QSAR Studies on Propafenone-Type Modulators of Multidrug Resistance" <i>Arch. Pharm. Pharm. Med. Chem.</i> , 331, pg. 233-240 (1998)
RO	98	Pearce, H. et al. "Structural characteristics of compounds that modulate P-Glycoprotein-associated multidrug resistance" <i>Advances In Enzyme Regulations</i> , 30, pg. 357-373, (1990)
RO	99	Safa, A. "Photoaffinity Labels for Characterizing Drug Interaction Sites of P-Glycoprotein" <i>Methods in Enzymology</i> , 292, pg. 289-307 (1998)
RO	100	Zhu, B. T. "A Novel Hypothesis for the Mechanism of Action of P-Glycoprotein as a Multidrug Transporter" <i>Molecular Carcinogenesis</i> , 25, pg. 1-13 (1999)
RO	101	Robert, J. "Proposals for Concomitant Use of several modulators of Multidrug Resistance in Clinics" <i>Anticancer Research</i> , 14, pg. 2371-2374 (1994)
RO	102	Hemenway, C. et al. "Immunosuppressant Target Protein FKBP12 Is Required for P-Glycoprotein Function in Yeast" <i>The Journal of Biological Chemistry</i> , 271, pg. 18527-18534 (1996)
RO	103	Tiberghien, F. et al. "Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay" <i>Anti-Cancer Drugs</i> , 7, pg. 568-578 (1996)
RO	104	Scala, S. et al. "P-Glycoprotein Substrates and Antagonists Cluster into Two Distinct Groups" <i>Molecular Pharmacology</i> , 51, pg. 1024-1033 (1997)
RO	105	Garigos, M. et al. "Competitive and non-competitive inhibition of the multidrug-resistance associated P-glycoprotein ATPase further experimental evidence for a multisite model" <i>Euro J. Biochem.</i> 244, pg. 664-673 (1997)
RO	106	Litman, T. et al. "Structure-activity relationships of P-glycoprotein interacting drugs: kinetic characterization of their effects on ATPase activity" <i>Biochimica et Biophysica Acta</i> , 1361, pg. 159-168, (1997)
RO	107	Wiese, M. et al. "Molecular modeling study of the multidrug resistance modifiers cis- and trans-flupentixol." <i>Pharmazie</i> , 52, pg. 679-685 (1997)
RO	108	Norman, B. "Inhibitors of MRP1-mediated multidrug resistance" <i>Drugs of the Future</i> , 23, pg. 1001-1013 (1998)
RO	109	Robert, J. "Multidrug resistance reversal agents" <i>Drugs of the Future</i> , 22, pg. 149-158 (1997)
RO	110	Ambudkar, S. et al. "Biochemical, Cellular, and Pharmacological Aspects of the multidrug transporter" <i>Annu. R v. Pharmacol. Toxicol.</i> , 39, pg. 361-398, (1999)
RO	111	Sharom, F. et al. "Spectroscopic and biophysical approaches for studying the structure and function of the P-glycoprotein multidrug transporter" <i>Biochim. Biophys. Acta</i> , 76, pg. 695-708 (1998)

CanCen Research  
52 pg. 421-429  
(1992)



P&G Cas 8375  
FORM PTO-1449  
7 of 10

RECEIVED

OTHER DOCUMENTS Continued

JUL 03 2002

RO	112	Borst, P., "Multidrug resistance: A solvable problem?" <i>Annals of Oncology</i> , 10, pg. S152-S164, (1999)
RO	113	Sonneveld, P. "Drug Resistance in Multiple Myeloma" <i>Pathologie of Blood</i> , 10, pg. 100-104, (1999)
RO	114	Loor, F. "Valspodar: Current status and Perspectives" <i>Expert Opin. Invest. Drugs</i> , 8, pg. 1003-1004, (1999)
RO	115	Ojima, I. et al "Designing taxanes to treat multidrug-resistant tumors" <i>Mod. in Drug Discovery</i> , pg. 45-52 (1999)
RO	116	Ueda, K. et al "Recent progress in P-Glycoprotein research" <i>Anti-Cancer Drug Design</i> , 14, pg. 115-121 (1999)
RO	117	Ford, J. et al "Pharmacologic circumvention of multidrug resistance" <i>Cytotechnology</i> , 12, pg. 171-212, (1993)
RO	118	Sonneveld, P. et al "Inhibitors of multidrug resistance" <i>Current Opinion in Oncology</i> , 9, pg. 543-548, (1997)
RO	119	Hegewisch-Becker, S. "MDR1 Reversal: Criteria for clinical trials designed to overcome the multidrug resistance phenotype" <i>Leukemia</i> , 10, pg. S32-S38, (1996)
RO	120	Volm, M. "Multidrug Resistance and its Reversal" <i>Anticancer Research</i> , 18, pg. 2905-2918 (1998)
RO	121	Kavallaris, M. "The role of multidrug resistance-associated protein (MRP) expression in multidrug resistance" <i>Anti-Cancer Drugs</i> , 8, pg. 17-25, (1997)
RO	122	Patel, N. et al "Multidrug resistance in cancer chemotherapy" <i>Investigational New Drugs</i> , 12, pg. 1-13, (1994)
RO	123	Hegewisch-Becker, S. et al "The MDR phenotype in hematologic malignancies: prognostic relevance and future perspectives" <i>Ann Hematol</i> , 72, pg. 105-117 (1996)
RO	124	Prost, S. "Mechanisms of Resistance to Topoisomerase Poisons" <i>Gen. Pharmac</i> , 26, pg. 1773-1784 (1995)
RO	125	Aszalos, A. "Modulation of Multidrug Resistance in Cancer by Immunosuppressive Agents" <i>Pathology Oncology Research</i> , 1, pg. 64-70, (1995)
RO	126	Tsuruo, T. et al "Multidrug Resistance" <i>Anti-cancer Drugs</i> , 6, pg. 213-218 (1995)
RO	127	Caponigro, F. et al "Protein kinase C: a worthwhile target for anticancer drugs?" <i>Anti-cancer Drugs</i> , 8, pg. 26-33 (1997)
RO	128	Simon, S. et al "Cell biological mechanisms of multidrug resistance in tumors" <i>Proc. Natl. Acad. Sci.</i> , 91, pg. 3497-3504, (1994)
RO	129	Loor, F. "Cyclosporins and Related Fungal Products in the Reversal of P-Glycoprotein-mediated Multidrug resistance" <i>Multidrug Resistance in Cancer Cells</i> , Chapter 26, pg. 385-412, (1996)
RO	130	Lum, B. et al "Molecular Targets in Oncology: Implications of the Multidrug Resistance Gene" <i>Pharmacotherapy</i> , 13, pg. 88-109, (1993)
RO	131	Sinha, B. "Topoisomerase Inhibitors" <i>Drugs</i> , 49, pg. 11-19, (1995)
RO	132	Naito, M. et al "New Multidrug-resistance-reversing drugs, MS 209 and SDZ PSC 833" <i>Cancer Chemother Pharmacol</i> , 40, pg. S20-S24, (1997)
RO	133	Ramu, A. et al "Reversal of multidrug resistance by phenothiazines and structurally related compounds" <i>Cancer Chemother Pharmacol</i> , 30, pg. 165-173 (1992)
RO	134	Ramu, A. et al "Reversal of multidrug resistance by bis(phenylalkyl)amines and structurally related compounds" <i>Cancer Chemother Pharmacol</i> , 34, pg. 423-430, (1994)
RO	135	Demeule, M. et al "Inhibition of P-glycoprotein by cyclosporin A analogues and metabolites" <i>Biochem. Cell Biol.</i> , 77, pg. 47-58, (1999)
RO	136	Norman, B. et al "Reversal of Resistance in multidrug resistance protein (MRP1)-overexpressing cells by LY329146." <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , 9, pg. 3381-3386, (1999)
RO	137	He, H. et al "Fumitremorgin C Analogs that reverse mitoxantrone resistance in human colon carcinoma cells" <i>Med. Chem. Res.</i> , 9, pg. 424-437 (1999)
RO	138	Sparreboom, A. et al "Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein" <i>Anti-Cancer Drugs</i> , 10, pg. 719-728, (1999)
RO	139	Hooijberg, J. et al "Potent interaction of flavopiridol with MRP1" <i>British Journal of Cancer</i> , 8, pg. 269-276 (1999)
RO	140	Drewe, J. et al "HIV Protease Inhibitor Ritonavir: A More Potent Inhibitor of P-Glycoprotein than the Cyclosporine Analog SDZ PSC 833" <i>Biochemical Pharmacology</i> , 57, pg. 1147-1152, (1999)
RO	141	Mendez-Vidal, C. et al "Reversal of P-glycoprotein-mediated multidrug resistance in vitro by AV200, a new ardeemin derivative" <i>Cancer Letters</i> , 132, pg. 45-50, (1998)
RO	142	Dantzig, A. et al "Selectivity of the Multidrug Resistance Modulator, LY335979, for P-Glycoprotein and Effect on Cytochrome P-450 Activities" <i>The Journal of Pharmacology and Experimental Therapeutics</i> , 290, pg. 854-862, (1999)
RO	143	Ecker, G. et al "The Importance of a Nitrogen Atom in Modulators of Multidrug resistance" <i>Molecular Pharmacology</i> , 56, pg. 791-796 (1999)
RO	144	Lehne, G. et al "Growth inhibition, cytokinesis failure and apoptosis of multidrug-resistant leukemia cells after treatment with P-glycoprotein inhibitory agents" <i>Leukemia</i> , 13, pg. 768-778 (1999)
RO	145	Regina, A. et al "Dexamethasone Regulation of P-Glycoprotein Activity in an Immortalized Rat Brain Endothelial Cell Line, GPNT" <i>Journal of Neurochemistry</i> , 73, pg. 1954-1963, (1999)

27, pg 182-187  
1999  
Invest Drugs  
8, pg 807-835  
1999

COPY OF PAPERS  
ORIGINALLY FILED



RECEIVED

P&G Case 8375  
FORM PTO-1449  
JUL 03 2002 Sheet 8 of 10

OTHER DOCUMENTS Continued

TECH CENTER 1600/2900

RO	146	Kim, S. et al "Sesquiterpene Esters from <i>Celastrus orbiculatus</i> and their structure-activity relationship on the modulation of multidrug resistance" <i>J. Nat. Prod.</i> , 62, pg. 697-700, (1999)
RO	147	Greenberger, L. et al "A-(3,4-Dimethoxyphenyl)-3,4-dihydro-6,7-dimethoxy-a-[(4-methylphenyl)thio]-2(1H)-iso-quinolineheptanenitrile (CL329,753): A Novel Chemotherapeutic Agent for P-Glycoprotein-Mediated Resistance with Improved Biological Properties Compared with Verapamil and Cyclosporine A" <i>Oncology Research</i> , 8, pg. 207-218, (1996)
RO	148	Nakanishi, O. et al "Potentiation of the Antitumor Activity by a Novel Quinoline Compound, MS-209, in Multidrug-Resistant Solid Tumor Cell Lines", <i>Oncology Research</i> , 9, pg. 61-69 (1997)
RO	149	Kraus-Berthier, L. et al, "In Vivo reversal of multidrug resistance by two new dihydropyridine derivatives, S16317 and S16324," <i>Acta Oncologica</i> , 33, pg. 631-637, (1994)
RO	150	Sato, W. et al "Reversal of multidrug resistance by a novel quinoline derivative, MS-209", <i>Cancer Chemother Pharmacol</i> , 35, pg. 271-277 (1995)
RO	151	O'Connell, C. et al "Synthesis and Evaluation of Hapalosin and analogs as MDR-Reversing agents" <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , 9, pg. 1541-1546 (1999)
RO	152	Halt, W. et al "Rational design and pre-clinical pharmacology of drugs for reversing multidrug resistance" <i>Biochemical Pharmacology</i> , 43, pg. 103-107, (1992)
RO	153	Liu, Z. et al "BIBW22 BS, Potent Multidrug resistance-Reversing Agent, Binds directly to P-Glycoprotein and Accumulates in Drug-Resistant Cells", <i>Molecular Pharmacology</i> , 50, pg. 482-492, (1996)
RO	154	Kwon, Y. et al "Inhibitors of P-Glycoprotein-mediated Daunomycin Transport in Rat Liver Canalicular Membrane Vesicles" <i>Journal of Pharmaceutical Sciences</i> , 85, pg. 935-939, (1996)
RO	155	Twentyman, P. et al "Effects of cyclosporin A and a non-immunosuppressive analogue, O-acetyl cyclosporin A, upon a growth of parent and multidrug resistant human lung cancer cells <i>in vitro</i> ", <i>Br. J. Cancer</i> , 65, pg. 335-340 (1992)
RO	156	Okuno, T. et al "Chemical Study on Hapalosin, a Cyclic Dipeptide Possessing Multidrug Resistance Reversing activities: Synthesis, Structure and Biological Activity" <i>Tetrahedron</i> , 52, pg. 14723-14734 (1996)
RO	157	Tanaka, K. et al "Effect of Cyclosporin Analogues and FK506 on Transcellular Transport of Daunorubicin and Vinblastine via P-glycoprotein" <i>Pharmaceutical Research</i> , 13, pg. 1073-1077 (1996)
RO	158	Rao, U. et al "Direct Demonstration of High affinity Interactions of Immunosuppressant Drugs with the Drug Binding Site of the Human P-Glycoprotein" <i>Molecular Pharmacology</i> , 45, pg. 773-776, (1994)
RO	159	Toffoli, G. et al "Reversal activity of Cyclosporin A and its metabolites M1, M17 and M21 in Multidrug-resistant cells" <i>Int. J. Cancer</i> , 71, pg. 900-906 (1997)
RO	160	Demeule, M. et al "Molecular Interactions of Cyclosporin A with P-Glycoprotein" <i>Journal of Biological Chemistry</i> , 272, pg. 6647-6652 (1997)
RO	161	Saeki, T. et al "Human P-glycoprotein transports Cyclosporin A and FK506" <i>The Journal of Biological Chemistry</i> 268 pg. 6077-6080 (1993)
RO	162	Sharom, F. et al "Synthetic hydrophobic peptides are substrates for P-Glycoprotein and stimulate drug transport" <i>Biochem. J.</i> 320, pg. 421-428 (1996)
RO	163	Kim, A. et al, "Saquinavir, an HIV Protease Inhibitor, Is Transported by P-Glycoprotein" <i>The Journal of Pharmacology and Experimental Therapeutics</i> , 266, pg. 1439-1445 (1998)
RO	164	Chiba, P. et al "Studies on propafenone-type modulators of multidrug resistance VI. Synthesis and pharmacological activity of compounds with varied spacer length between the central aromatic ring and the nitrogen atom" <i>Il Farmaco</i> , 53, pg. 357-364 (1998)
RO	165	Motohashi, N. et al "Drug Resistance Reversal, Anti-mutagenicity and Antiretroviral Effect of Phthalimido- and Chloroethyl-Phenothiazines" <i>Anticancer Research</i> , 17, pg. 3537-3544 (1997)
RO	166	De Jong, G. et al "Modulation of Doxorubicin Resistance in P388 ADR Cells by Ro44-5912, a Tiapamil Derivative" <i>Anticancer Research</i> , 15, pg. 911-916 (1995)
RO	167	Campolongo, L. et al "Reversal of multidrug resistance by new dihydropyridines with low calcium antagonist activity" <i>Acta Oncologica</i> 33, pg. 787-791 (1994)
RO	168	Etlevant, C. et al "Requirements for P-glycoprotein recognition based on structure-activity relationships in the podophyllotoxin series" <i>Anti-Cancer Drug Design</i> 13, pg. 317-336 (1998)
RO	169	Shrivastava, P. et al "Circumvention of multidrug resistance by a quinoline derivative, MS-209, in multidrug-resistant human small-cell lung cancer cells and its synergistic interaction with cyclosporin A or verapamil" <i>Cancer Chemother Pharmacol</i> 42, pg. 483-490 (1998)
RO	170	Yang, J. et al "Inhibitory Effect of Alkylating Modulators on the Function of P-Glycoprotein" <i>Oncology Research</i> , 9, pg. 477-484, (1997)
RO	171	Thirumalaiah, K. et al "Characterization of 2-Chloro-N <sup>10</sup> -Substituted Phenoxazines for Reversing Multidrug Resistance in Cancer cells" <i>Oncology Research</i> , 10, pg. 29-41, (1998)
RO	172	Naito, S. et al "Development of Novel Reversal Agents, Imidazothiazole Derivatives, targeting MDR1 and MRP-Mediated Multidrug Resistance." <i>Oncology Research</i> , 10, pg. 123-132 (1998)
RO	173	Ramu, N. et al "Circumvention of Adriamycin Resistance by Dipyrromethane Analogues: a structure-activity relationship study" <i>Int. J. Cancer</i> , 43, pg. 487-491, (1989)

COPY OF PAPERS  
ORIGINALLY FILED



RECEIVED P&G Case 8375

FORM PTO-1449

Sheet 9 of 10

JUL 03 2002

OTHER DOCUMENTS Continued

TECH CENTER 1600/2900

Resistance against human tumour

Ro	174	Hill, B. et al "Evaluation of S9788 as a Potential Modulator of Drug Resistance against Human Tumour Sublines Expressing Different Resistance Mechanisms <i>in vitro</i> " <i>Int. J. Cancer</i> , 55, pg. 330-337 (1993)
Ro	175	Sato, S. et al "Potentiation of vincristine and etoposide by a new synthetic imidazole anti-tumor agent YM534 active against human cancer cells and multidrug-resistant cells" <i>Anti-Cancer Drug Design</i> , 4, pg. 125-135, (1989)
Ro	176	Nerasaki, F. et al "A novel quinoline derivative, MS-209, overcomes drug resistance of human lung cancer cells expressing the multidrug resistance-associated protein (MRP) gene" <i>Cancer Chemother Pharmacol</i> , 40, pg. 425-432 (1997)
Ro	177	Tekeshita, H. et al "Avoidance of Doxorubicin Resistance in Osteosarcoma Cells Using a New Quinoline Derivative, MS-209" <i>Anticancer Research</i> , 18, pg. 739-742 (1998)
Ro	178	Boer, R. et al "Modulation of P-glycoprotein Mediated Drug Accumulation in Multidrug Resistant CCRF VCR-1000 Cells by Chemosensitisers" <i>European Journal of Cancer</i> , 32A, pg. 857-861 (1996)
Ro	179	Van Rensburg, C. et al, "Novel tetramethylpiperidine-substituted phenazines are potent inhibitors of P-glycoprotein activity in a multidrug resistant cancer cell line" <i>Anticancer Drugs</i> , 8, pg. 708-713 (1997)
Ro	180	Choi, S. et al "The bisbenzylisoquinoline alkaloids, tetrastine and fangchinoline, enhance the cytotoxicity of multidrug resistance-related drugs via modulation of P-glycoprotein." <i>Anticancer Drugs</i> , 9, pg. 255-261 (1998)
Ro	181	Abderrabi, M. et al "Comparative <i>in vitro</i> evaluation of dithiane analogs of tiapamil, Ro 11-2933, Ro 44-5911 and Ro 44-5912 as multidrug resistance modulators" <i>Anti-Cancer Drugs</i> , 7, pg. 430-436 (1996)
Ro	182	Kim, S. et al "Circumvention of drug resistance in cancer cells by a new fluoropyrimidine analogue" <i>Experimental and Molecular Medicine</i> , 28, pg. 119-123, (1996)
Ro	183	Christensen, J. et al "Reversal of multidrug resistance by derivatives of acrivastine: a study of structure-activity relationships of P-glycoprotein inhibitors <i>in vitro</i> and <i>in vivo</i> " <i>Oncology Reports</i> , 4, pg. 1353-1360 (1997)
Ro	184	Thimmaiah, K. et al "Structural Determinants of Phenoxazine Type Compounds Required to Modulate the Accumulation of Vinblastine and Vincristine in Multidrug-resistant cell lines" <i>Cancer Communications</i> , 2, pg. 249-259, (1990)
Ro	185	Smith, A. et al "Availability of PSC833, a Substrate and Inhibitor of P-Glycoproteins, in Various Concentrations of Serum" <i>Journal of the National Cancer Institute</i> , 90, pg. 1161-1166, (1998)
Ro	186	Seprodi, J. et al "Peptide derivatives Against Multidrug Resistance" <i>Peptides, Proceedings of the 24<sup>th</sup> European Peptide Symposium</i> , pg. 801-802, (1996)
Ro	187	Suzuki, T. et al "Structure-Activity Relationship of Newly Synthesized Quinoline derivatives for Reversal of Multidrug Resistance in Cancer" <i>J. Med. Chem.</i> , 40, pg. 2047-2052 (1997)
Ro	188	Chiba, P. et al "Substituted 4-Acylpyrazoles and 4-Acylpyrazolones" <i>Synthesis and Multidrug Resistance-Modulating Activity</i> <i>J. Med. Chem.</i> , 41, pg. 4001-4011 (1998)
Ro	189	Suzuki, T. et al "Synthesis of Glucuronides of multidrug resistance Reversing Drug MS-209" <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , 9, pg. 659-662 (1999)
Ro	190	Nakamura, S. et al "Effects of Isoquinolinesulphonamide Compounds on Multidrug-resistant P388 cells" <i>J. Pharm. Pharmacol</i> , 45, pg. 268-273 (1993)
Ro	190	Ogino, J. et al "Dendroamides, New Cyclic Hexapeptides from a Blue-Green Alga. Multidrug-Resistance Reversing activity of dendroamide A." <i>J. Nat. Prod.</i> , 59, pg. 581-586 (1996)
Ro	191	Kim, E. et al, "A New Sesquiterpene Ester from <i>Celastrus orbiculatus</i> Reversing Multidrug Resistance in cancer Cells" <i>J. Nat. Prod.</i> , 61, pg. 108-111 (1998)
Ro	192	Lehner, M. et al "Phase II trial of dexamethasone and epirubicin in patients with non-responsive metastatic breast cancer" <i>British Journal of Cancer</i> , 77, pg. 1155-1163 (1998)
Ro	193	Dele, I. et al "Reversal of P-glycoprotein-mediated multidrug resistance by XR9051, a novel diketopiperazine derivative" <i>British Journal of Cancer</i> , 78, pg. 885-892 (1998)
Ro	194	Budworth, J. et al "Comparison of Staurosporine and four analogues: their effects on growth, rhodamine 123 retention and binding to P-glycoprotein in multidrug resistant MCF-7/Adr cells" <i>British Journal of Cancer</i> , 73, pg. 1063-1068 (1996)
Ro	195	Hurwitz, L. et al "Can prenylcysteines be exploited as ligands for mammalian multidrug-resistance transporters?" <i>Chemistry &amp; Biology</i> , 4, pg. 711-715 (1997)
Ro	196	Gekeler, V. et al "Effects of the selective bisindolylmaleimide protein kinase C inhibitor GF109203X on P-glycoprotein-mediated multidrug resistance" <i>British Journal of Cancer</i> , 74, pg. 897-905 (1996)
Ro	197	Newman, R. et al "MDL 201307: a novel benzothiazepine modulator of multiple drug resistance" <i>Journal of Experimental Therapeutics &amp; Oncology</i> , 1, pg. 109-118 (1996)
Ro	198	Jachez, B. et al "SDZ 280-125: a cyclopeptide endowed with an <i>in vitro</i> cyclosporin A-like profile of activity for the reversal of the P-glycoprotein-mediated multidrug resistance of tumor cells" <i>Anti-cancer drugs</i> , 5, pg. 313-320 (1994)
Ro	199	Jach, Z. B. et al "Reversion of the P-glycoprotein-mediated multidrug resistance of cancer cells by FK-506 derivatives" <i>Anti-cancer Drugs</i> , 4, pg. 223-229 (1993)
Ro	200	Fan, D. et al "Reversal of multidrug resistance in murine fibrosarcoma cells by thioxanthene flupentixol" <i>Investigational New Drugs</i> , 12, pg. 185-195, (1994)

COPY OF PAPERS  
ORIGINALLY FILED



RECEIVED P&G Case 8375  
FORM PTO-1449  
Sheet 10 of 10

OTHER DOCUMENTS Continued

JUL 03 2002

*Proteins by some substituted*

RO	201	Molnar, J. et al "Inhibition of the Transport Function of Membrane Phenothiazines in E. Coli and Multidrug Resistant Tumor Cells" <i>Anticancer Research</i> , 17, pg. 481-486 (1997)
RO	202	Teodon, E. et al "D sign, Synth sis, and in Vitro Activity of Catamphiphilic reverters of Multidrug Resistance: Discovery of a Selective, Highly Efficacious Chemosensitizer with Potency in the Nanomolar Range" <i>J. Med. Chem.</i> , 42, pg. 1687-1697, (1999)
RO	203	Van Asperen, J. et al "The Pharmacological Role of P-Glycoprotein in the Intestinal Epithelium", <i>The Italian Pharmacological Society</i> , (1998)
RO	204	Wacher, V. et al "Role of P-Glycoprotein and Cytochrome P450 3A in Limiting Oral Absorption of Peptid s and Peplidomimetics" <i>Journal of Pharmaceutical Sciences</i> 87, pg. 1322-1330, (1998)
RO	205	Matsuzaki, J. et al "Contribution of P-glycoprotein to Bunitrolol Efflux across Blood-Brain Barrier" <i>Biopharmaceutics and Drug Disposition</i> , 20, pg. 85-90(1999)
RO	206	Sanglard, D. et al "Mechanisms of Resistance to azole Antifungal Agents in Candida albicans Isolates from AIDS Patients Involve Specific Multidrug Transporters" <i>Antimicrobial Agents and Chemotherapy</i> , 39, pg. 2378-2386 (1995)
RO	207	Li, X. et al "Role of Efflux Pump(s) in Intrinsic Resistance of Pseudomonas aeruginosa: Active Efflux as a contributing Factor a B-Lactam Resistance" <i>Antimicrobial Agents and Chemotherapy</i> , 38, pg. 1742-1752 (1994)
RO	208	Van Veen, H. et al "The ABC family of multidrug transporters in microorganisms" <i>Biochimica et Biophysica Acta</i> , 1365, pg. 31-36 (1998)
RO	209	Kim, A. et al "Saquinavir, an HIV Protease Inhibitor, Is Transported by P-Glycoprotein", <i>Journal Pharm. And Experimental Therapeutics</i> , 286, pg. 1439-1445 (1998)
RO	210	Lee, I. et al "Protease Inhibitors and the MDR1 Multidrug Transporter" <i>The Journal of Clinical Investigation</i> , 101, pg. 287-288 (1998)
RO	211	Renau, T. et al "Chapter 12. Antimicrobial Potentiation Approaches: Targets and Inhibitors" <i>annual Reports in Medicinal Chemistry</i> , 33, pg. 121-129 (1998)
EXAMINER <i>R. Desai</i>		DATE CONSIDERED <i>11-14-2002</i>
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

Patent and Trademark Office - U.S. DEPARTMENT OF COMMERCE

COPY OF PAPERS  
ORIGINALLY FILED



1449 11/20/02

Following is a list of the references from the IDS filed on July 3, 2002 which are illegible because of the stamp through the citation:

- 28 - TASAKA, S. et al., "Synthesis of 2-phenylimidazo [2,1-b]benzothiazole derivatives as modulators of multidrug resistance for tumor cells," J. Heterocyclic Chem., 34, pg. 1763-1767 (1997)
- 57 - Borrel, M. et al., "The effect of crown ethers, tetraalkylammonium salts, and polyoxyethylene amphiphiles on pirarubicin incorporation in K562 resistant cells," Biochemical Pharmacology, 50, pg. 2069-2076 (1995)
- 84 - Klopman, G. et al., "Structure-activity study and design of multidrug-resistant reversal compounds by a computer automated structure evaluation methodology," Cancer Research, 52, pg. 4121-4129 (1992)
- 113 - Sonneveld, P. "Drug resistance in multiple myeloma," Pathologie et Biologie, 27, pg. 182-187 (1999)
- 114 - Loor, F., "Valspodar: current status and perspectives," Expert Opin. Invest Drugs, 8, pg. 807-835 (1999)
- 174 - Hill, B. et al., "Evaluation of S9788 as a potential modulator of drug resistance against human tumour sublines expressing differing resistance mechanisms in vitro," Int. J. Cancer, 55, pg. 330-337 (1993)
- 201 - Molnar, J. et al., "Inhibition of the transport function of membrane proteins by some substituted phenothiazines in E. coli and multidrug resistant tumor cells," Anticancer Research, 17, pg. 481-486 (1997)